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In contrast to secondary lymphoid organs (SLOs) that arise during development at 
predetermined locations, the formation of tertiary lymphoid organs (TLOs) can occur 
in adults at ectopic sites in any tissue in the context of persistent inflammatory 
disorders, such as autoimmune diseases, cancer, and organ transplantation(1-3). 
The molecular mechanisms underlying the organization of chronic inflammatory 
infiltrates into ectopic lymphoid tissue recapitulatesome of those involved in lymphoid 
organogenesisduring development(4, 5) and hence this process hasbeen referred to 
as lymphoid neogenesis. Beyond anatomical similarities with SLOs, ectopic lymphoid 
tissues are fully functional and support the development of local adaptive immune 
responses, including the priming of naive lymphocytes (6), generation of memory 
subsets, and germinal center reactions (clonal expansions, somatic hypermutations, 
immunoglobulin class switching and antibody production), which are suspected to 
contribute to the exacerbation ofchronic inflammatory diseases (7, 8). 
1/ TLOs in rejected organs 
We have undertaken several studies in the context of alloimmunity and have 
demonstrated 1/ that the graft is not only the target of the alloimmune response but 
also a site where this response actually develops, so as to optimize the 
communication between the targeted tissue and the immune effectors(9), 2/ that 
TLOs provide survival signal to B-cells, allowing them to escape rituximab-induced 
apoptosis, thereby thwarting therapeutic efficiency (10), 3/ that anti-MHC humoral 
response is more intense and more diverse in TLOs [the abnormal activation of 
CD4+ T cells promotes the development of an exaggerated pathogenic immune 
humoral response in TLOs due to a defective immune regulation(11) and the 
intragraft microenvironment interferes with peripheral deletion of autoreactive 
immature B cells that, in turn, produce antibodies against intracellular autoantigens 
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(12)], 4/ that intragraft humoral immune response appears uncoupled from the 
systemic response and that TLO formation recapitulate organogenesis of SLOs (13). 
While these data demonstrate that chronic rejection isassociated with the 
development of lymphoid nodularinfiltrates within rejected organs, evidence for the 
involvement of these lymphoid structures in the rejection process came from a model 
of rat aortic interposition model where lymphoid nodular infiltrates was evidenced in 
the adventitia of the chronically rejected aorticgrafts (3). We could demonstrate that 
nodular lymphoidstructures were functional ectopic germinal centers thatparticipate 
in the rejection process of the grafted organ. In addition, this showed that the 
vascular stroma was sufficient to promote and support lymphoid neogenesis. 
2/ TLOs in atherothrombosis 
Interestingly, TLOs are also present in the context of atherothrombosis. Indeed, 
TLOs were detected in the adventitia of human atherosclerotic arteries as early as 
the 1950s(14), a process that has been recently revisited(15-18). We couldalso 
characterize adventitial lymphoid aggregates distributed all along the aortic segment 
in atherosclerosis-prone ApoE KO mice. These structures were defined as TLOs 
because they are composed of B cell follicles surrounded by T cells, a prototypic 
organization reported for ectopic germinal centers(4). IgM and IgD staining revealed 
the presence of two subsets of B cells with different maturation states. Moreover, 
these TLOs included blood vessels, lymphatic networks, and FRC-like cells, 
suggesting that these aggregates are proper structures to induce and maintain local 
immune responses. These adventitial blood and lymphatic networks are essential for 
the recruitment and drainage of immune effectors(19-22). Interestingly, the TLOs 
were polarized towards the media, suggesting that effectors inside the aortic wall 
may be involved in the lymphangiogenesis and angiogenesis associated with the 
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formation of adventitial TLOs. In this respect, it is important to note that human 
VSMCs are able to trigger intramural angiogenesis through the production of VEGF-
A(23). 
3/ Mechanisms of lymphoid neogenesis in the aorta 
A detailed characterization of TLOs in ApoE KO mouse aortas showed that vascular 
smooth muscle cells (VSMCs) in the media express the chemokines CXCL13, 
CCL19, CCL21, and CXCL16, triggering the recruitment of leukocytes to the 
adventitia(16). This raised the question of the identity of the cellular and molecular 
factors that confer an organizer (LTo) potential upon VSMCs. We hypothesized that 
macrophages could act as Lymphoid Tissue inducer (LTi) cells in diseased arteries. 
Indeed, macrophages are key players in host defense and tissue homeostasis and 
are heterogeneous and plastic cells that can mount different programs of polarized 
activation according to microenvironmental cues (24). M1-polarized macrophages 
are considered as pro-inflammatory cells that produce high levels of effectors, such 
as the cytokine interleukin-1β, while M2-polarized macrophages are rather reparative 
cells, promoting the synthesis of extracellular matrix components. In the context of 
advanced atheroma, plaque-infiltrated macrophages have an M1 pro-inflammatory 
profile(25, 26). 
Our data suggest that M1 inflammatory macrophages are relevant LTi candidates 
because they express high LT-α and TNF-α levels. However, instead of acting 
through “classical” cell-cell interactions that characterize LTo induction, intimal 
macrophages assume an LTi role remotely, via soluble factors, thus endowing 
VSMCs with LTo functions. We further showed that the effect of M1 macrophages on 
VSMCs involved TNFR1/2 signaling and was LTβR-independent 
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The results obtained in vitrowere corroborated by those collected in anin vivo aortic 
transposition model. Indeed, we demonstrated the presence of adventitial aortic 
TLOs in LTβR KO segments that had been transplanted into ApoE KO mice. 
Together, these findings demonstrate that, in the context of atherosclerosis-
associated lymphoid neogenesis, LTβR signaling is dispensable. 
To definitively validate these observations, we used collagen scaffolds seeded with 
VSMCs that had been stimulated ex vivo with M1 conditioned medium (CM) or with 
control media. These scaffolds were then implanted subcutaneously in mice. Three 
weeks after implantation, we found that scaffolds seeded with M1 CM-stimulated 
VSMCs contained lymphoid cell aggregates, which were not detected in scaffolds 
containing unstimulated VSMCs. The lymphoid cells that composed these 
aggregates were CD3+ T and B220+ B cells. SMA-positive VSMCs surrounding the 
aggregates expressed CCL19, CCL20, and CXCL16.  
In summary, for the first time, our most recent data show that classical LTi cells 
might not be mandatory for the development of TLOs, a role that can be assumed by 
macrophages. Indeed, in the context of atherosclerosis, soluble mediators produced 
by intimal M1 macrophages activate medial VSMCs through their TNF receptors 
independently of LTβR signaling. These findings support the hypothesis that radial 
hydraulic conductance conveys information from the intima toward the adventitia in 
the following manner: intimal macrophages transmit LTi-inducing signals to medial 
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